ideaSpace, University of Cambridge
Elpis Biomed provides differentiated human cells and tissue models for science, drug discovery, and toxicology, based on disruptive technology called reprogramming. The company aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery & development purposes.
Elpis Biomed’s innovation is the ability to ‘forward program’ human induced pluripotent stem cells (iPSC) through insertion of specific genetic elements at defined positions within the human genome. Elpis Biomed’s proprietary technology allows rapid generation of highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells to be sold to academic research groups and pharma/biotech customers.